BMS Orencia SC gets FDA nod for RA treatment
The SC formulation of Orencia is a fixed 125mg dose which can be given weekly through an injection under the skin following a single IV loading dose of
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.